Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

April 05, 2006 09:00 ET

Holmes Herbs, Inc.: Clinical Study Manager Appointed

SCOTTSDALE, ARIZONA--(CCNMatthews - April 5, 2006) - Holmes Herbs, Inc. (OTCBB:HMHB) announces the appointment of Mr. Andrew Nehls as Clinical Study Manager for its clinical operations in Omaha, Nebraska. Mr. Nehls comes to the company with a strong project management and pharmaceutical background.

Mr. Nehls holds a Masters degree in Pharmaceutical Sciences, Drug Delivery from the University of Nebraska Medical Center, Omaha, NE, and a Professional Project Management Graduate Certificate from Western Carolina University, Cullowhee, NC. He also holds a Bachelors of Science degree.

His professional experience includes working as Product Manager for Streck Laboratories, Inc. where he was responsible for project management and marketing of chemistry & quality control device products. His experience also includes working as a Pharmaceutical Sales Representative for Forest Pharmaceuticals, Inc.. He started his professional career serving as a Pharmaceutical Research Assistant at the University of Nebraska Medical Center.

"We are very excited to have someone of Andrews' experience and academic background join our research team. His exuberance and management skills make him a great addition to our team," said Mark McDonald, Executive Director.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information